Stratos Wealth Advisors LLC Makes New $2.02 Million Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Stratos Wealth Advisors LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 83,475 shares of the biopharmaceutical company's stock, valued at approximately $2,024,000. Stratos Wealth Advisors LLC owned approximately 0.07% of Catalyst Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CPRX. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at $27,000. Park Square Financial Group LLC bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth $29,000. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals in the 1st quarter worth $64,000. Farther Finance Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 1,495 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the completion of the sale, the insider directly owned 41,081 shares of the company's stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gary Ingenito sold 44,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the sale, the insider directly owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 247,924 shares of company stock valued at $5,879,369. Insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

CPRX opened at $20.75 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $15.19 and a 52-week high of $26.58. The company's 50-day simple moving average is $23.61 and its two-hundred day simple moving average is $22.89. The stock has a market capitalization of $2.53 billion, a P/E ratio of 13.22, a P/E/G ratio of 0.85 and a beta of 0.66.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.